Amneal Pharmaceuticals cash flow, quarter by quarter

In Q2 2026, Amneal Pharmaceuticals generated −$21.2M of operating cash flow and spent $30.7M on capital projects, leaving free cash flow of −$51.9M. That is $113M less than in Q2 2025 ($61.0M).

Over the twelve months to Jun 30, 2026, operating cash flow was $201M; the largest uses were other financing ($2.8B), other investing ($139M), capital spending ($72.9M); besides operations, cash came from net borrowing (+) / repaid (−) ($2.9B), shares issued ($1.3M); the cash balance rose by $55.9M.

Operating cash flow was −$21.2M against net income of $69.6M — -0.3× profit, less cash than reported earnings, worth checking against working capital. The largest differences: receivables −$170M, inventory −$69.2M, payables +$66.7M.

Amneal Pharmaceuticals is burning cash: its operations consume cash, a free cash flow of −$208M a year at the current rate against $128M of cash and investments: a runway of about 7 months; $6.0M of debt also comes due within a year, which would need refinancing or new money before any new financing.